Other Development Costs. Other than the Development Costs to be paid or borne by Otsuka pursuant to this Section 6.4.1, Acucela shall be solely responsible for all Development Costs with respect to Collaboration Compounds and Collaboration Products in the Field in the Shared Territory incurred by Acucela, except to the extent set forth in Section 6.6.
Other Development Costs. In addition to the provisions of Section 6.1.1 (i.e., for activities other than the POC Activities), Oncothyreon will be responsible for [*] of the Development Costs of the Product incurred in accordance with the Development Plan and Budget, and Array will be responsible for [*] of such Development Costs; provided that, following Completion of the POC Activities, Array’s share of such Development Costs will be increased to [*] (and Oncothyreon’s share will be decreased to [*]) until the aggregate amounts of the increased Development Costs (i.e., the amounts greater than [*]) so paid by Array, together with all amounts paid pursuant to Section 6.1.5, if any, equal one-half of the POC Development Costs that exceed [*] (such one-half of amounts over [*] referred to herein as the “POC Reimbursement Amount”), it [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. being understood that if the POC Reimbursement Amount exceeds the increased Development Costs (i.e., the amounts greater than [*]) paid under this Section 6.1.2 (together with the amounts paid pursuant to Section 6.1.5), then such excess amount (“POC Unreimbursed Amount”) shall be paid to Oncothyreon pursuant to Section 10.2.2. Within twenty-one (21) days following completion of the POC Activities, Oncothyreon shall provide a written statement of the total POC Reimbursement Amount (if any) to Array.
Other Development Costs. Xxxxxxx shall be responsible for one hundred percent (100%) of the Collaboration CMC Costs for any Phase 3 Clinical Trial(s) incurred by either Party or any of their Affiliates and all other costs of Development of the Initial Compound, Initial Product, 2nd Generation Compounds and 2nd Generation Products other than as set forth in Sections 3.9.2, 7.2.1 and 7.2.2.
Other Development Costs. Pfizer shall be responsible for paying [***] percent ([***]%) of any Development Costs which are not referenced in Section 6.3(a) through Section 6.3(g) above (“Additional Development Costs”), and such Additional Development Costs shall be treated as [***]. [***] Redacted pursuant to a confidential treatment request.
Other Development Costs. Xxxxxxx shall bear all Phase 1 Development Costs and Phase 2 Development Costs other than those described in Section 7.2.1 and Section 7.2.2 as being the responsibility of Protagonist. In addition, Xxxxxxx shall be responsible for one hundred percent (100%) of the CMC Development Costs for any Phase 3 Clinical Trial(s) incurred by either Party or any of their Affiliates and all other costs of Development of the Initial Compound, Initial Product, 2nd Generation Compounds and 2nd Generation Products other than as set forth in Sections 4.2.5, 7.2.1 and 7.2.2. For clarity, the costs for which Xxxxxxx is responsible pursuant to this Section 7.2.3 include costs incurred prior to the Restatement Date.
Other Development Costs. Except for Development Costs allocated to AEVI in respect of the initial indication in the Field for the Licensed Product in the European Union or that AEVI and KKC agree to incur in respect of additional indications as set forth in Section 8.2.1(a)(iii), KKC will be solely responsible for Development Costs incurred in Developing any Licensed Product (a) outside the Field in the Territory and (b) outside the Territory.
Other Development Costs. Except as otherwise expressly provided in this Agreement or agreed to by the Parties in writing, each Party shall be responsible for all costs (other than Development Costs shared by the Parties pursuant to the other provisions of this Section 3.7.1) incurred by it in connection with the research and Development of Products or MDX-1379 under this Agreement; provided, however, that, except as otherwise expressly provided in this Agreement, BMS shall reimburse Medarex for any such reasonable and verifiable costs incurred by Medarex or its Affiliates for activities that are requested by BMS or required as an obligation of Medarex by this Agreement in connection with the Development of Products or MDX-1379 solely for use in the Royalty Territory (other than Development Costs shared by the Parties pursuant to the other provisions of this Section 3.7.1) or the Development of Products for Partially Co-Funded Indications in the Territory and, subject to Medarex’s obligation to share certain costs with respect to the maintenance of Initial Regulatory Approvals as set forth in Section 3.7.1(d), the Development of Non-Co-Promoted Products for an Indication other than in support of obtaining either the Initial Regulatory Approval or, if applicable, the initial Compendia Listing, for such Indication in the United States.
Other Development Costs. Travel expenses, application fees, site ----------------------- option payments and other miscellaneous costs incurred by USGen, MEI and EPC.
Other Development Costs. Except for Development Costs allocated to Medgenics in respect of the initial indication in the Field for the Licensed Product in the European Union or that Medgenics and KHK agree to incur in respect of additional indications as set forth in Section 8.2.1(a)(iii), KHK will be solely responsible for Development Costs incurred in Developing any Licensed Product (a) outside the Field in the Territory and (b) outside the Territory.
Other Development Costs. Development Costs incurred pursuant to the Global Development Plan other than Development Costs allocated pursuant to Section 3.2 and other than Development Costs exclusively related to either the Licensed Territory or the MERRIMACK Territory (and paid directly by either XXXXXX or MERRIMACK pursuant to Section 3.4) shall be shared equally between XXXXXX and MERRIMACK. XXXXXX shall pay to MERRIMACK XXXXXX’x share of such Development Costs incurred by MERRIMACK, within [**] days following MERRIMACK’s invoice therefor, and MERRIMACK shall pay to XXXXXX MERRIMACK’s share of such Development Costs incurred by XXXXXX, within [**] days following XXXXXX’x invoice therefor.
